Searching... Searching...
  • NVP + NA
  • Köp NA
  • Sälj NA
  • Senast NA
  • SEK

  • Buy NA
  • Sell NA
  • Latest NA
  • USD

Focus areas

NeuroVive’s research currently covers four segments where the company’s in-depth mitochondrial know-how has the potential to make a substantial improvement to care.

Mitochondrial disorders, including Complex I Dysfunction

Primary mitochondrial disorders are either caused by genetic changes in mitochondrial DNA or mutations in nuclear DNA. The precise incidence of these mitochondrial disorders is unknown, and many individuals with mitochondrial disease have not been diagnosed. As a group, mitochondrial disorders are one of the most common hereditary illnesses cited in international medical literature, with an estimated 10 people in every 100,000 having a primary mitochondrial disorder.

Mitochondrial myopathy
Mitochondrial myopathies are a group of neuromuscular diseases caused by damage to the mitochondria. The symptoms of mitochondrial myopathies include muscle weakness, exercise intolerance and fatigue, and are often accompanied by other symptoms of primary mitochondrial disorders. The prognosis for these disorders ranges in severity from progressive weakness to death and there is a high unmet medical need of new and effective treatment options.

Traumatic Brain Injury (TBI)

TBI is one of the most common causes of death and disability in children and young people worldwide. In TBI, nerve cells are damaged immediately. The damage then continues to exacerbate several days after the initial trauma, which often has a significant effect on the extent of the injury.

NASH – an out-licensing project

Non-alcoholic steatohepatitis (NASH) involves fat incorporation in the liver in combination with inflammation. The condition may develop into liver cirrhosis or hepatocellular cancer (HCC). There is a strong association between NASH and a variety of metabolic syndromes like diabetes and obesity. Approximately 3-5% of Americans (approx. 15 million people) suffer from NASH and there are currently no registered drugs for the treatment of this condition.

Hepatocellular carcinoma – an out-licensing project

Liver cancer is often diagnosed at a late stage of the disease and mortality rates are high. There are two major types of liver cancer: hepatocellular carcinoma (HCC) and intrahepatic bile duct cancer. Risk factors associated with HCC are hepatitis B virus or hepatitis C virus infections, alcohol-induced cirrhosis or chronic liver damage. Although liver cancer is less common in northern Europe and the US than In Asia, HCC is the sixth most-common type of cancer and the third most-common cause of death worldwide.

IR Contact

Catharina Johansson

Catharina Johansson


+46 (0) 46-275 62 21